Overview

Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)

Status:
Terminated

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safe range of single doses of rhASM administered to adults with ASM deficiency.

Phase:

Phase 1

Details

Lead Sponsor:

Genzyme, a Sanofi Company